In 1995, highly effective inactivated hepatitis A vaccines were first licensed in the United States for preexposure prophylaxis against hepatitis A virus (HAV) among persons aged > or =2 years. In 2005, vaccine manufacturers received Food and Drug Administration approval for use of the vaccines in children aged 12-23 months.